摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要:
A bead feeder for serially delivering beads to a downstream location comprises a bead supply wheel which rotates about a vertical axis. The bead supply wheel includes a bead supply bowl and a plurality of radially arranged channels below the bowl connected to rotate with the bowl. Discharge openings in the bowl are in alignment with the radially arranged channels to delivery beads to those channels, and a bead receiving pocket is positioned at the outer end of each channel. A transfer wheel picks up beads from the bead receiving pockets and transfers those beads to a delivery wheel by vacuum transfer and release. The delivery wheel serially delivers the beads to the downstream location.
摘要:
A computer program product that provides a graphical user interface for configuring communication information for multiple network service providers on a computer system. The program product is operable to display a network communication scene that includes edit windows and selectable options for a user to view, enter, remove, and modify configuration information for at least one network service provider, and allows the user to enter information for establishing communication with the same network service provider using at least two different communication mediums, and from several different geographical locations.
摘要:
A bead feeder for serially delivering beads to a downstream location comprises a bead supply wheel which rotates about a vertical axis. The bead supply wheel includes a bead supply bowl and a plurality of radially arranged channels below the bowl connected to rotate with the bowl. Discharge openings in the bowl are in alignment with the radially arranged channels to delivery beads to those channels, and a bead receiving pocket is positioned at the outer end of each channel. A transfer wheel picks up beads from the bead receiving pockets and transfers those beads to a delivery wheel by vacuum transfer and release. The delivery wheel serially delivers the beads to the downstream location.
摘要:
Compounds having the formula (I) or (II), are useful as p38 kinase inhibitors, wherein R is an optionally substituted alkyl, cycloalkyl, or aryl; R6 is hydrogen or lower alkyl; R7 is hydrogen or a non-interfering substituent, and Q is a non-aromatic moiety as defined in the specification.
摘要翻译:具有式(I)或(II)的化合物可用作p38激酶抑制剂,其中R是任选取代的烷基,环烷基或芳基; R 6是氢或低级烷基; R 7是氢或非干扰取代基,Q是说明书中定义的非芳族部分。
摘要:
A method for determining the dosage regime of a drug suitable for use in the treatment of a neurological condition in a subject, which method comprises typing the SCN1A gene of the subject. The method may be used to determine the dosage regime of an anti-epileptic drug (AED) in a subject. A subject may be treated in accordance with the dosage regime determined using such a method.